预约演示
更新于：2025-05-16
Bumetanide
布美他尼
更新于：2025-05-16
概要
基本信息
药物类型 小分子化药 |
别名 3-(aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid、3-butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid、3-butylamino-4-phenoxy-5-sulfamoyl-benzoic acid + [20] |
作用方式 抑制剂 |
作用机制 NKCC1抑制剂(溶质载体家族12成员2抑制剂)、NKCC2抑制剂(钠钾氯协同转运蛋白-2抑制剂)、SLC12A4抑制剂(solute carrier family 12 member 4 inhibitors) |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 日本 (1976-04-08), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H20N2O5S |
InChIKeyMAEIEVLCKWDQJH-UHFFFAOYSA-N |
CAS号28395-03-1 |
关联
46
项与 布美他尼 相关的临床试验NCT06941415
Bumetanide vs. Furosemide for Adults Hospitalized With Cirrhosis: the BUFF Trial
CTR20240307
中国健康受试者单次口服布美他尼片（1mg）的开放、随机、单剂量、两制剂、单次给药、交叉设计的生物等效性试验
NCT06036914
Ultra High Dose Diuretic Strategy for Management of Acute Decompensated Heart Failure - A Randomized, Double-Blind Pilot Trial
100 项与 布美他尼 相关的临床结果
登录后查看更多信息
100 项与 布美他尼 相关的转化医学
登录后查看更多信息
100 项与 布美他尼 相关的专利（医药）
登录后查看更多信息
3,800
项与 布美他尼 相关的文献（医药）2025-06-01JOURNAL OF HAZARDOUS MATERIALS
Broad-spectrum antibody against thiazides and degraded salamide and immunoassay establishment for simultaneous detection
Article
作者: Li, Yunlong ; Wen, Jiaxin ; Zhang, Shiwei ; Pan, Liangwen ; Lei, Hongtao ; Huang, Xin-An ; Luo, Hewen ; Tang, Yu ; Liu, Zhiwei ; Chen, Jiahong
The illegal additive thiazides and degraded salamide in food supplements poses significant health risks and regulatory challenges. However, the structural differences between thiazides and salamide complicate the hapten design for immunoassay detection. In this study, we first outlined the common skeleton of thiazides and their shared epitopes with salamide through molecular overlap and atomic charge distribution analysis. Several haptens were rationally designed based on the private epitope of salamide and the shared epitopes with thiazides, assisted by computer-aided chemical analysis. Subsequently, the resultant monoclonal antibody exhibited broad specificity for thiazides (IC50 value = 21.43-405.40 ng/mL) and salamide (IC50 value = 0.76 ng/mL). The immunoassay affinities of 5 of these thiazides are reported for the first time. Further elucidation of the intrinsic recognition mechanism was achieved through homology modeling and molecular docking, clarifying the antibody's diverse recognition spectrum. Finally, we established a rapid, reliable colloidal gold-based immunochromatography strip for simultaneous detecting total thiazides and degraded salamide in food supplements and surface water sample for the first time. The cut-off value was as low as 7.5 ng/mL, which was 32 times more sensitive than that of established immunoassays for thiazides.
2025-05-01JOURNAL OF NEUROSCIENCE RESEARCH
Modulation of GABAergic System in a Chicken Retinal Ischemic Model: The Role of Chloride Cotransporters
Article
作者: Miya‐Coreixas, V. S. ; Santos, G. F. ; Araújo, D. S. M. ; Calaza, K. C. ; Nascimento, T. H. O. ; Nascimento, A. A. ; Brito, R.
ABSTRACT:
Retinal ischemia is a significant pathological condition that contributes to visual impairment and neuronal cell death in various retinopathies. Evidence suggests that GABA release during ischemic events may exhibit neuroprotective properties, but conflicting findings highlight a potential shift in its effects due to altered chloride ion homeostasis. This study aimed to investigate the role of the GABAergic system in retinal ischemia, focusing on the temporal dynamics of GABA release and its impact on retinal damage. We hypothesized that ischemia‐induced changes in GABA transport and chloride ion equilibrium contribute to neuronal damage, which can be mitigated by modulating GABAergic activity. Using an ex vivo chick retina model subjected to oxygen and glucose deprivation (OGD), during different times, we assessed morphological changes, cell death, GABA levels, transporter activity, and the levels of chloride cotransporters NKCC1 and KCC2. Pharmacological interventions, including picrotoxin and bumetanide, were used to evaluate neuroprotective effects. Our results revealed that OGD‐induced significant morphological changes and cell death in the retina. GABA levels were reduced in a GAT‐1‐dependent manner, while picrotoxin and bumetanide demonstrated neuroprotective effects by mitigating retinal swelling and modulating the GABAergic system. Notably, OGD increased NKCC1 content, but not KCC2 levels, indicating a disruption in chloride homeostasis. These findings suggest that ischemia‐induced alterations in GABAergic activity and chloride transport contribute to retinal damage. Targeting these pathways with pharmacological agents, such as bumetanide, may offer therapeutic strategies for mitigating ischemic retinal injury. Further research is recommended to explore the clinical applicability of these findings in the ischemic retina.
2025-04-01TRENDS IN PHARMACOLOGICAL SCIENCES
Emerging autism and Fragile X syndrome treatments
Review
作者: Salmaso, Natalina ; D'Angiulli, Amedeo ; Parkhill, Michael ; Aguilar-Valles, Argel ; Lee, Vivian
The limitations of current symptom-focused treatments drive the urgent need for effective therapies for autism and Fragile X syndrome (FXS). Currently, no approved pharmacological interventions target the core symptoms of these disorders. Advances in understanding the underlying biology of autism and FXS make this an important time to explore novel options. Indeed, several treatments have recently been tested in clinical trials, with promising results in treating core symptoms of autism and FXS. We focus on emerging interventions, such as gut microbiome therapies, anti-inflammatory approaches, bumetanide, phosphodiesterase 4D inhibitors, and endocannabinoid modulators. We also discuss factors, such as disorder heterogeneity, which may have contributed to poor efficacy in previously failed late-phase trials and impact recent trials, emphasizing the need for personalized treatment approaches.
100 项与 布美他尼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏衰竭 | 加拿大 | 1993-12-31 | |
| 高钙血症 | 中国 | 1982-01-01 | |
| 高钾血症 | 中国 | 1982-01-01 | |
| 高血压 | 中国 | 1982-01-01 | |
| 低钠血症 | 中国 | 1982-01-01 | |
| 中毒 | 中国 | 1982-01-01 | |
| 水肿 | 日本 | 1976-04-08 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 自闭症谱系障碍 | 临床3期 | 巴西 | 2018-09-24 | |
| 自闭症谱系障碍 | 临床3期 | 巴西 | 2018-09-24 | |
| 自闭症谱系障碍 | 临床3期 | 法国 | 2018-09-24 | |
| 自闭症谱系障碍 | 临床3期 | 法国 | 2018-09-24 | |
| 自闭症谱系障碍 | 临床3期 | 德国 | 2018-09-24 | |
| 自闭症谱系障碍 | 临床3期 | 德国 | 2018-09-24 | |
| 自闭症谱系障碍 | 临床3期 | 匈牙利 | 2018-09-24 | |
| 自闭症谱系障碍 | 临床3期 | 匈牙利 | 2018-09-24 | |
| 自闭症谱系障碍 | 临床3期 | 意大利 | 2018-09-24 | |
| 自闭症谱系障碍 | 临床3期 | 意大利 | 2018-09-24 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 211 | (BUMETANIDE (S95008) Followed by Open-Label S95008) | 獵簾網衊鑰窪淵鏇襯鏇 = 鹹鹽壓鑰選簾壓網憲壓 襯窪餘網遞糧獵鹹醖醖 (構窪願糧範築選網餘獵, 膚願構顧範艱構蓋積顧 ~ 網蓋範積壓鏇顧憲簾衊) 更多 | - | 2023-06-05 | ||
PLACEBO for week 0 - 26+Open-Label BUMETANIDE (S95008) for weeks 26 - 52 (PLACEBO Followed by Open-Label S95008) | 獵簾網衊鑰窪淵鏇襯鏇 = 鏇蓋築鑰範齋選繭簾簾 襯窪餘網遞糧獵鹹醖醖 (構窪願糧範築選網餘獵, 製遞蓋網顧襯鹹艱蓋築 ~ 壓糧製齋顧獵繭壓齋鑰) 更多 | ||||||
临床2期 | 34 | 淵觸選憲膚蓋糧觸廠簾(醖窪壓襯顧鬱淵鑰醖蓋) = 憲糧鏇淵遞構遞憲網膚 糧築製襯遞餘醖淵齋獵 (製鹽鏇艱齋齋鬱膚鹹鏇 ) 更多 | - | 2022-09-20 | |||
Bumetanide plus placebo | 淵觸選憲膚蓋糧觸廠簾(醖窪壓襯顧鬱淵鑰醖蓋) = 鹽獵顧淵鏇鏇蓋積淵窪 糧築製襯遞餘醖淵齋獵 (製鹽鏇艱齋齋鬱膚鹹鏇 ) 更多 | ||||||
N/A | 130 | 艱憲願鏇蓋獵膚夢簾夢(鏇繭鹽積願遞壓蓋製鏇) = The use of IV bumetanide in patients hospitalized for AHF exacerbations is associated with a 7.17% yearly incidence of acute gout flares 鏇鬱鑰淵選蓋鏇壓膚糧 (觸築鏇糧鑰築艱糧獵築 ) 更多 | - | 2020-06-03 | |||
临床2期 | 34 | (Placebo) | 淵膚製窪壓廠選糧築醖(鬱膚鹹積簾觸簾遞夢窪) = 繭憲選壓衊夢鬱鑰觸壓 襯網餘膚範廠廠鏇遞繭 (願築淵蓋鑰齋襯鹹築築, 1.78) 更多 | - | 2020-03-10 | ||
(Treatment Grup) | 淵膚製窪壓廠選糧築醖(鬱膚鹹積簾觸簾遞夢窪) = 製齋壓繭醖遞遞製觸鏇 襯網餘膚範廠廠鏇遞繭 (願築淵蓋鑰齋襯鹹築築, 3.29) 更多 | ||||||
临床4期 | 34 | (Acetazolamide/Low-dose Loop Diuretics, Upfront Spironolactone) | 鬱範餘糧鹽繭膚醖鹹簾(艱獵窪簾夢鑰簾壓積糧) = 簾醖繭鬱醖糧獵觸選選 繭選餘積艱顧獵獵餘蓋 (製製範夢鏇網糧齋襯積, 133) 更多 | - | 2019-03-21 | ||
(High-dose Loop Diuretics, Upfront Spironolactone) | 鬱範餘糧鹽繭膚醖鹹簾(艱獵窪簾夢鑰簾壓積糧) = 選積窪蓋網醖衊廠鑰簾 繭選餘積艱顧獵獵餘蓋 (製製範夢鏇網糧齋襯積, 165) 更多 | ||||||
N/A | 新生儿癫痫 追加 | - | Phenobarbital + Placebo | 醖夢範網憲築壓築築鏇(觸製淵鹹獵獵壓鏇蓋襯) = p=0.02 壓獵鬱憲蓋衊齋築繭夢 (夢齋廠願遞積膚衊窪艱 ) 更多 | 积极 | 2018-10-05 | |
N/A | 癫痫发作 辅助 | - | 餘簾製觸遞獵觸餘廠遞(觸築醖衊願築壓遞構築) = comparable between subjects receiving bumetanide vs. phenobarbital alone 遞範糧淵鹹艱夢壓觸繭 (糧廠醖積築繭遞壓襯襯 ) 更多 | 积极 | 2015-09-25 | ||
N/A | - | 鹹膚憲願夢鑰淵顧壓膚(遞壓襯壓網衊糧夢選衊) = 鬱遞遞鹽廠淵願廠憲網 獵網鹽簾廠糧醖繭憲壓 (獵鑰顧壓淵齋顧構觸醖, 0.2) | - | 2007-11-04 | |||
鹹膚憲願夢鑰淵顧壓膚(遞壓襯壓網衊糧夢選衊) = 壓製齋醖網網積願齋繭 獵網鹽簾廠糧醖繭憲壓 (獵鑰顧壓淵齋顧構觸醖, 0.2) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用